Angioslide, founded in 2005 by Eran Hirszowicz and Amos Nahir, is a privately-held medical device company dedicated to provide physicians with cost effective, innovative products for emboli management during vascular interventions. The company markets the PROTEUS™ device family, the only FDA cleared device that enables physicians to capture and remove embolic particles dislodged at the lesion site in peripheral arteries.
Distal embolization is a common complication of interventions to treat PAD. Angioslide helps physicians to manage embolic load released during procedures by providing an easy-to-use, efficient, and cost-effective embolic removal angioplasty solution for the peripheral vascular disease market. The PROTEUS embolic capture feature is uniquely integrated into an angioplasty balloon, providing onsite embolic removal at the point of disruption through the device suction mechanism.
PROTEUS It is the first device of its kind to receive both CE and FDA clearances for use in lower limbs. A multi-center trial conducted at leading European medical centers has demonstrated the device's ability to remove embolic particles (debris, thrombus) and function as a PTA balloon.
Angioslide’s innovative, pioneering team is committed to bringing our Embolic Capture Angioplasty (ECA) technology to the forefront of peripheral vascular disease Market.